Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer to exit from Chinese generic drug JV with Hisun
The JV was formed in September 2012 by Pfizer with Zhejiang Hisun Pharmaceuticals (Hisun) with a total investment of $295m and a capital of $250m. Hisun will remain
The JV was formed in September 2012 by Pfizer with Zhejiang Hisun Pharmaceuticals (Hisun) with a total investment of $295m and a capital of $250m. Hisun will remain
The deal gives Sanofi an exclusive, worldwide license to develop and commercialize PRN2246, which is presently in clinical development. Under the deal, Principia will receive $40m upfront payment, future milestone payments
Under the deal, the partnership will use MiNA’s small activating RNA (saRNA) therapeutics platform to develop novel compounds for the treatment of fibrotic liver diseases such as NASH.
The trial known as MONALEESA-7 met its primary endpoint of progression-free survival (PFS), stated Novartis. Through the late-stage trial, the CDK4/6 inhibitor Kisqali in combination with oral hormonal
The NEPLEX (nephron on a chip with cellular and extracellular matrix complexity) consortium will aggregate crucial technologies to develop and build a novel drug discovery device called Nephron-on-a-Chip.
Zelboraf has been approved for the first line treatment of patients with Erdheim-Chester disease (ECD) and who are positive for BRAF V600 mutation. ECD is a rare and serious
The company has submitted marketing authorization application (MAA) to the EMA for Kymriah to treat children and young adults with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia
The buyer will pay Valeant a 6% royalty on worldwide sales of libido drug Addyi (flibanserin), beginning 18 months from the signing of the sale agreement. In August 2015, Valeant
A research in this regard was carried out by investigators at the Stanford University School of Medicine in California. The scientists say that the new treatment option can
The research collaboration and license agreement between the partners pertains to the discovery and development of GalXC RNAi therapeutics, with an initial focus on NASH. A chronic liver